Order 3, Get Your 4th Free!* | Learn More >>
Mouse Insulin-like Growth Factor I (mIGF-I)
Growth Factors and Cytokines

Mouse Insulin-like Growth Factor I (mIGF-I) #9897

Reviews ()
Citations (0)
Mouse Insulin-like Growth Factor I (mIGF-I): Image 1

The ability of mIGF-I to induce phosphorylation of Akt was assessed. After serum starvation, NIH/3T3 cells were treated with increasing concentrations of mIGF-I for 10 minutes. Cells were lysed, and phospho-Akt was quantified using PathScan® Phospho-Akt (Thr308) Sandwich ELISA Kit #7252. OD450 is shown.

Mouse Insulin-like Growth Factor I (mIGF-I): Image 2

The proliferation of primary human dermal fibroblasts treated with increasing concentrations of mIGF-I was assessed. After 72 hour treatment with mIGF-I, cells were incubated with a tetrazolium salt and the OD450 - OD650 was determined.

Mouse Insulin-like Growth Factor I (mIGF-I): Image 3

The purity of recombinant mIGF-I was determined by SDS-PAGE of 6 µg reduced (+) and non-reduced (-) recombinant mIGF-I and staining overnight with Coomassie Blue.

Mouse Insulin-like Growth Factor I (mIGF-I): Image 4

Western blot analysis of extracts from NIH/3T3 cells, untreated or treated with increasing concentrations of mIGF-I for 10 minutes, using Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb #4060 (upper) and Akt1 (C73H10) Rabbit mAb #2938 (lower).


With carrier: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl and 20 μg BSA per 1 μg mIGF-I. Carrier free: Lyophilized from a 0.22 μm filtered solution of 20 mM citrate, pH 3.0 containing 100 mM NaCl.


Stable in lyophilized state at -20°C for 1 year after receipt. Sterile stock solutions reconstituted with carrier protein are stable at 4°C for 2 months and at -20°C for 6 months. Avoid repeated freeze-thaw cycles. Maintain sterility. Storage at -20°C should be in a manual defrost freezer.

Product Description


>98% as determined by SDS-PAGE of 6 μg reduced (+) and non-reduced (-) recombinant mIGF-I. All lots are greater than 98% pure.

Molecular Formula

Recombinant mIGF-I has a Met on the amino terminus and has a calculated MW of 7,808. DTT-reduced and non-reduced protein migrate as 6 kDa polypeptides. The expected amino-terminal MGPET of recombinant mIGF-I was verified by amino acid sequencing.

Source / Purification

Recombinant mouse IGF-I (mIGF-I) Gly33-Ala102 (Accession #NP_001104746) was produced in E. coli at Cell Signaling Technology.


Most circulating endocrine-acting IGF-I is produced by hepatocytes, and paracrine- or autocrine-acting IGF-I is produced by defined cell types within specific tissues (1,2). Many neoplastic cells produce IGF-I, which regulates a number of cellular processes including energy metabolism, proliferation, and cell survival (3,4). IGF-I activity is regulated by one or more of the six extracellular IGF-binding proteins (IGFBPs). IGFBPs bind to IGF-I, and most inhibit the binding between IGF-I and the IGF-I receptor (IGFIR) (1,2). Some IGFBPs may increase cell responses to IGF-I. Binding of IGF-I to IGFIR activates the Akt, JNK, and Erk pathways (2). IGF-I and IGFIR are frequently expressed by cancer cells and may contribute to the proliferation and viability of a number of cancer types (1,2).

  1. Pollak, M. (2008) Nat Rev Cancer 8, 915-28.
  2. Chitnis, M.M. et al. (2008) Clin Cancer Res 14, 6364-70.
  3. Karey, K.P. and Sirbasku, D.A. (1988) Cancer Res 48, 4083-92.
  4. Small, T.W. and Pickering, J.G. (2009) J Biol Chem 284, 24684-95.

Pathways & Proteins

Explore pathways + proteins related to this product.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST's products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST's Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PathScan is a trademark of Cell Signaling Technology, Inc.
To Purchase # 9897SC
Product # Size Price
50 µg  (With Carrier) $ 201
50 µg  (Carrier Free) $ 201